Mudita Advisors LLP Has $1.77 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Mudita Advisors LLP lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 64.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,607 shares of the medical research company's stock after selling 17,100 shares during the quarter. Charles River Laboratories International makes up 1.0% of Mudita Advisors LLP's investment portfolio, making the stock its 16th largest holding. Mudita Advisors LLP's holdings in Charles River Laboratories International were worth $1,773,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Pinnacle Bancorp Inc. grew its stake in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $37,000. GeoWealth Management LLC boosted its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International during the fourth quarter worth approximately $48,000. Finally, Tortoise Investment Management LLC boosted its position in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Up 1.5%

Shares of NYSE:CRL traded up $2.11 during trading on Friday, hitting $141.00. 1,473,414 shares of the company were exchanged, compared to its average volume of 982,521. The stock has a market cap of $6.93 billion, a price-to-earnings ratio of 940.00, a P/E/G ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The firm has a fifty day moving average price of $135.94 and a two-hundred day moving average price of $165.27. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.27 EPS. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick bought 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 5,040 shares of company stock valued at $807,407 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday. Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Finally, Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $172.31.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).